Brian Dyck
Overview
Explore the profile of Brian Dyck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
66
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McQuown S, Xia S, Baumgartel K, Barido R, Anderson G, Dyck B, et al.
Front Mol Neurosci
. 2019 Feb;
12:21.
PMID: 30792627
Augmentation of cyclic nucleotide signaling through inhibition of phosphodiesterase (PDE) activity has long been understood to enhance memory. Efforts in this domain have focused predominantly on PDE4, a cAMP-specific phosphodiesterase...
2.
Bookser B, Weinhouse M, Burns A, Valiere A, Valdez L, Stanczak P, et al.
J Org Chem
. 2018 May;
83(12):6334-6353.
PMID: 29790748
Alkylation of 4-methoxy-1 H-pyrazolo[3,4- d]pyrimidine (1b) with iodomethane in THF using NaHMDS as base selectively provided N2-methyl product 4-methoxy-2-methyl-2 H-pyrazolo[3,4- d]pyrimidine (3b) in an 8/1 ratio over N1-methyl product (2b)....
3.
Dyck B, Branstetter B, Gharbaoui T, Hudson A, Breitenbucher J, Gomez L, et al.
J Med Chem
. 2017 Apr;
60(8):3472-3483.
PMID: 28406621
A series of potent thienotriazolopyrimidinone-based PDE1 inhibitors was discovered. X-ray crystal structures of example compounds from this series in complex with the catalytic domain of PDE1B and PDE10A were determined,...
4.
Dyck B, Tamiya J, Jovic F, Pick R, Bradbury M, OBrien J, et al.
J Med Chem
. 2008 Oct;
51(22):7265-72.
PMID: 18954038
Thien-2-yl 1S,2R-milnacipran analogues were synthesized and characterized as norepinephrine/serotonin transporter inhibitors. These compounds possessed higher potencies than 1S,2R-milnacipran (2R-1) while maintaining low molecular weight and moderate lipophilicity, which are the...
5.
Zhang M, Jovic F, Vickers T, Dyck B, Tamiya J, Grey J, et al.
Bioorg Med Chem Lett
. 2008 Jun;
18(13):3682-6.
PMID: 18539031
Compounds with various activities and selectivities were discovered through structure-activity relationship studies of bicifadine analogs as monoamine transporter inhibitors. The norepinephrine-selective 2-thienyl compound S-6j was efficacious in a rodent pain...
6.
Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, et al.
Bioorg Med Chem Lett
. 2008 May;
18(11):3230-5.
PMID: 18468895
A series of milnacipran analogs containing a heteroaromatic group were synthesized and studied as monoamine transporter inhibitors. Many compounds exhibited higher potency than milnacipran at NET and NET/SERT with no...
7.
Tamiya J, Dyck B, Zhang M, Phan K, Fleck B, Aparicio A, et al.
Bioorg Med Chem Lett
. 2008 May;
18(11):3328-32.
PMID: 18445525
A series of milnacipran analogs were synthesized and studied as monoamine transporter inhibitors, and several potent compounds with moderate lipophilicity were identified from the 1S,2R-isomers. Thus, 15l exhibited IC(50) values...
8.
9.
Chen C, Dyck B, Fleck B, Foster A, Grey J, Jovic F, et al.
Bioorg Med Chem Lett
. 2008 Jan;
18(4):1346-9.
PMID: 18207394
Derivatives of milnacipran were synthesized and studied as monoamine transporter inhibitors. Potent analogs were discovered at NET (9k) and at both NET and SERT (9s and 9u). A pharmacophore model...
10.
Rowbottom M, Vickers T, Tamiya J, Zhang M, Dyck B, Grey J, et al.
Bioorg Med Chem Lett
. 2007 Mar;
17(8):2171-8.
PMID: 17350839
The design, synthesis, and SAR of a series of substituted spirohydantoins are described. Optimization of an in-house screening hit gave compounds that exhibited potent binding affinity and functional activity at...